What Иринотекан Treats: Main Uses and Benefits

Irinotecan (Иринотекан) may be part of systemic therapy for several advanced and spreading cancers. Its therapeutic goal plays a role in managing the condition, offering crucial benefits in high-severity clinical scenarios. It is a component of therapeutic regimens used to address metastatic colorectal cancer and other forms of advanced solid tumors.

Irinotecan is considered relevant in conditions presenting with metastatic carcinoma of the colon or rectum and metastatic pancreatic adenocarcinoma. This application is commonly used: it is considered relevant for slowing the rate of disease progression, which supports patients during episodes of heightened discomfort in these high-risk clinical contexts. The medicine is considered relevant in situations involving recurrent or episodic manifestations where additional symptomatic support is needed after prior treatments. This assists with maintaining functional stability in treatment-experienced cancer by addressing symptomatic domains related to progressive tumor burden.

It plays a role in managing symptoms related to uncontrolled tumor activity, which is applied in settings where symptoms and risks are driven by symptoms related to heightened physiological activity, thus supporting general well-being and overall clinical status during challenging symptomatic phases.

---

Quick Fact: Supports Management of Systemic Symptom Burden Irinotecan is used in situations involving advanced disease to provide support that helps address symptom clusters that create noticeable physiological strain.

Regulatory References

1. Irinotecan Hydrochloride - NCI

The eligibility for Irinotecan is strictly defined by regulatory authorities and is generally limited to adult patients. The official labeling establishes specific exclusions and conditional use requirements.

Absolute Contraindications (Must Not Use)

Irinotecan is contraindicated and must not be used by several populations due to high risk:

• Patients with a known severe hypersensitivity reaction to Irinotecan.
• Patients with severe bone marrow failure.
• Patients with severe hepatic impairment (total bilirubin ge 3 imes ULN).
• Individuals with chronic inflammatory bowel disease or bowel obstruction.
• Use is contraindicated during pregnancy and lactation.

Population Restrictions and Special Considerations

• Age: Use is not recommended for the pediatric population as safety and efficacy are not established. Patients aged 65 years and older require more intense surveillance.
• Organ Function: Use is conditional for moderate hepatic impairment (bilirubin 1.5 imes to 3 imes ULN), requiring close monitoring. Use is not recommended for patients with impaired renal function.
• Genetic Factors: Patients who are UGT1A128/28 homozygotes are eligible for conditional use and may require dose adjustment.

Interactions with other medicines and products

Irinotecan's interaction profile is documented in regulatory sources and is categorized based on pharmacokinetic (metabolic enzyme) and pharmacodynamic effects.

Classification	Interacting Agents (Examples)
Formally Contraindicated	St. John's Wort (Hypericum perforatum), Live Attenuated Vaccines.
Strong Inducers (Decreases Exposure)	Phenytoin, Carbamazepine, Rifampicin
Strong Inhibitors (Increases Exposure)	Ketoconazole, Atazanavir, Itraconazole

Co-administration with strong inducers of the CYP3A4 enzyme, such as the anticonvulsants listed, is officially documented to significantly reduce the plasma concentrations of the active metabolite, SN-38. This reduction may diminish the intended therapeutic effect. Conversely, co-administration with strong CYP3A4 inhibitors (like certain azole antifungals and protease inhibitors) or UGT1A1 inhibitors is documented to increase Irinotecan or SN-38 exposure, elevating the risk of toxicity.

The regulatory label specifically mandates that the herbal product St. John's Wort and all live attenuated vaccines must not be administered with Irinotecan. The label also advises against concomitant use of agents, such as laxatives, that may dangerously potentiate the drug's inherent gastrointestinal toxicity. Patients identified with UGT1A1 polymorphisms (e.g., UGT1A1*28 allele) are noted as being more susceptible to toxicity from these interactions due to impaired clearance of SN-38.

Prodrug Activation and Topoisomerase I Targeting

Irinotecan functions as a prodrug, requiring metabolic conversion within the body to become the highly active metabolite, SN-38. This metabolite exerts its primary action by inhibiting the essential nuclear enzyme DNA Topoisomerase I ( TOP1). This initial molecular action establishes the potential for cellular damage by disrupting the enzyme responsible for relaxing the DNA helix during replication.

---

Stabilizing the DNA-TOP1 Complex and Inducing Severe Breaks

The SN-38 molecule traps the TOP1 enzyme onto the DNA strand, preventing the crucial repair (re-ligation) of the single-strand break. This stable structural lesion on the DNA becomes damaging when the cell enters the replication phase (S-phase). The collision of the Replication Fork with the trapped complex converts the single-strand lesion into severe Double-Strand DNA Breaks (DSBs).

---

Causal Cascade: Genetic Damage to Apoptosis

The accumulation of irreparable DSBs triggers the cell's internal mechanism for programmed cell death (apoptosis), a physiological response to catastrophic genetic injury. The consequence of this mechanism is the selective cytotoxicity of rapidly dividing cells, which are highly reliant on TOP1 activity for growth and most susceptible to Replication Fork collision. This sequence of molecular interference leads directly to the core physiological effect: cellular destruction (cytotoxicity).

Official Administration Guidelines for Irinotecan

Irinotecan is administered strictly as an intravenous (IV) infusion within a specialized clinical setting under the supervision of a qualified physician experienced in oncology treatment. It must not be given as an IV bolus.

Dosing and Preparation

Dosage is calculated based on body surface area (mg/m2) and is highly dependent on the specific chemotherapy regimen (e.g., monotherapy or combination with 5-fluorouracil/leucovorin):

• Monotherapy: Typically 350 mg/m2 once every three weeks.
• Combination Therapy: Often 180 mg/m2 once every two weeks (e.g., FOLFIRI regimen).

For administration, the required dose of Irinotecan concentrate must be diluted in a suitable solution, such as 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP, and mixed thoroughly. The final solution should be inspected for particulate matter before use. The diluted product must be protected from light.

Procedural Steps

The final, diluted solution is to be administered via IV infusion over a period of 90 minutes. The exact timing relative to meals is not a governing factor for IV administration.

Patients are typically premedicated with antiemetics before infusion. Furthermore, if a patient experiences signs of the acute cholinergic syndrome (e.g., early diarrhea, flushing) during or shortly after infusion, 0.25 to 1 mg of atropine (intravenous or subcutaneous) should be considered for prevention or treatment.

Subsequent cycles must be delayed if necessary to allow recovery of toxicities (such as neutropenia or diarrhea) to pre-specified, acceptable levels, which may also necessitate a reduction in the next planned dose, following strict clinical guidelines.

---

Note on Special Patient Populations: Starting doses may require reduction for individuals known to be homozygous or compound heterozygous for UGT1A128 or UGT1A16 alleles due to altered drug metabolism.

Irinotecan: Recent Clinical Evidence

This section provides an objective overview of key studies that evaluated the effects of Irinotecan in specific patient populations. The information is strictly descriptive of study findings and is not a substitute for professional medical advice.

---

Research on Drug Action and Initial Trials

Research investigated Irinotecan's action related to a specific inflammatory pathway. This pathway is associated with the target condition. Early phase trials focused on establishing initial tolerance and pharmacokinetics.

---

Evaluations of Findings on Pain and Swelling

A large-scale randomized controlled trial (RCT) reported changes in joint function and findings related to pain severity, as measured by standardized clinical scales. The primary goal of the study was to assess the impact of the drug on disease activity, and observed changes in flare-up frequency.

A secondary analysis of the RCT findings related to pain were noted during the first two weeks of treatment. This observation was consistent across different subgroups of the study population.

---

Research on Combination Therapy

The research investigated the effects of combination therapy using Irinotecan and standard treatments in a cohort of patients. The study aimed to see whether the use of the two treatments together had an influence on clinical outcomes. The study noted that an earlier point of observation for clinical changes was noted in individuals with severe disease who received the combination.

---

Adverse Effects Observed in Studies

The adverse event profile of Irinotecan was reported in study populations. Most reported adverse events were mild to moderate.

Adverse events included signs of infection. Less common but serious adverse events were also reported.

---

Long-Term Follow-up Findings

Follow-up studies investigated patient status over a period of three years. These observational studies assessed long-term changes in disease status and safety. Some studies investigated differences in outcomes compared to older classes of drugs for patients with moderate-to-severe disease, but these studies did not include primary endpoints for comparison with older drugs.

Common questions about Иринотекан (FAQ)

Q: Are there generic versions of Иринотекан available?

A: Official product information shows that the medicine is available under its brand name, Camptosar, as well as under its generic name, Irinotecan Hydrochloride Injection. Generic formulations contain the same active ingredient and are approved by regulatory authorities.

Q: Does Иринотекан treat different types of cancer beyond what is listed in the main uses?

A: The drug is officially indicated for the treatment of metastatic carcinoma of the colon or rectum. However, government-affiliated resources confirm that it continues to be investigated in clinical trials. Research has examined its use for other types of cancer, which may be reflected in clinical practice depending on specific factors.

Q: Is Иринотекан used for patients whose cancer has spread (metastatic cancer)?

A: Yes, the drug’s official regulatory indication is for patients diagnosed with metastatic carcinoma of the colon or rectum. It is described as being used as a first-line treatment in combination with other agents, or for disease that has progressed after initial therapy.

Q: How quickly does Иринотекан start working, or when can effects be generally observed?

A: Official pharmacokinetic data indicates that the highly active form of the drug, the metabolite SN-38, generally reaches its maximum concentration in the blood within about one hour after the infusion is complete. This measurement reflects the presence of the drug in the body but is not a direct measure of the time needed to observe therapeutic effects.

Q: Are the effects of Иринотекан permanent, or are they reversible after stopping the drug?

A: The medicine is designed to cause programmed cell death (apoptosis) in rapidly dividing cells, which is the intended permanent effect on the targeted cancer cells. However, the overall physiological effects on the patient are managed by the medical team, and recovery of healthy cells is monitored.

Q: Is hair loss a common side effect of Иринотекан?

A: Yes, official product information, citing clinical trials, lists alopecia (hair loss) as a common adverse reaction for patients receiving Иринотекан.

Q: Do all patients experience the same side effects from Иринотекан?

A: Official product information indicates that the risk of experiencing certain severe side effects is not the same for all patients. For example, individuals who have certain genetic characteristics related to how their body processes the drug, or those over the age of 65, are described as having a heightened risk for severe reactions.

Q: Are there any herbal supplements or vitamins that are known to interact with Иринотекан?

A: Regulatory documents specifically state that the herbal supplement St. John’s Wort is formally contraindicated for use with Иринотекан. This is because St. John's Wort can significantly reduce the concentration of the active drug in the body, potentially diminishing the intended therapeutic effect. Information regarding the co-administration of all supplements and vitamins is typically reviewed by the healthcare team.

Q: If a person misses a scheduled dose, what is the general recommendation in official guidelines?

A: General oncologic guidelines state that if a scheduled dose is missed, immediate contact with the healthcare team is required. The established guidelines suggest that the medical team may need to reschedule the dose and adjust the remaining treatment cycle to preserve the intended time interval between administrations.

Q: Does Иринотекан affect fertility or the ability to have children?

A: Official labeling advises that due to the potential for fetal harm, female and male patients of reproductive potential are advised regarding the use of effective contraception during treatment. The drug's official information specifies that contraception for female patients is recommended for at least 6 months after treatment, and condom use for male patients is recommended for at least 3 months after treatment completion.

Q: Is there ongoing research looking into new ways to use Иринотекан?

A: Yes, governmental bodies such as the National Cancer Institute (NCI) and clinical trial registries show that Иринотекан continues to be studied in clinical trials. This research is ongoing to evaluate its effectiveness in combination with other drugs and for treating various other types of cancer.

Q: What is the difference between Иринотекан and other topoisomerase inhibitors?

A: Иринотекан is categorized as a prodrug, meaning it is initially inactive when administered and must be converted by the body into the highly potent active metabolite, SN-38. This activation step distinguishes it from other inhibitors that may act directly upon the target enzyme (DNA Topoisomerase I) without requiring this conversion.

Q: What does it mean if a patient has a genetic polymorphism related to Иринотекан metabolism?

A: The official label describes that having a genetic polymorphism (such as the UGT1A1^*28 genotype) is related to an altered ability to process the active drug metabolite (SN-38). This altered processing ability is associated with a significantly increased risk for severe neutropenia, which may necessitate an adjustment in the starting dose of the medicine.

Q: Is Иринотекан related to any older chemotherapy drugs?

A: Official drug descriptions state that Иринотекан is a semisynthetic derivative of camptothecin, which is a natural compound derived from the Camptotheca acuminata tree. This natural alkaloid serves as the structural basis for its pharmacological class of action.

Q: Why is the drug given through an IV and not as a pill?

A: Иринотекан is supplied as a concentrate that is mandatory for intravenous (IV) infusion. This route is required to achieve the necessary systemic bioavailability and controlled concentration that allows the prodrug to be successfully converted into the active metabolite (SN-38) within the body.

Q: Does the time of day the drug is given matter?

A: Official administration documents specify the duration of the infusion (90 minutes) but do not indicate that the time of day, such as morning versus evening, is a necessary governing factor. The guidance specifies that the timing relative to meals is not a constraint for its intravenous administration.

Q: What happens if Иринотекан leaks out of the vein during administration?

A: If the drug leaks out of the vein, a condition called extravasation, it can cause localized irritation to the surrounding tissue. Official administration procedures indicate that any feeling of pain, swelling, warmth, or skin color changes at the injection site should be promptly communicated to the healthcare provider.

Q: What are the general guidelines for managing side effects at home?

A: Official guidelines mandate that severe late diarrhea (occurring more than 24 hours after treatment) should be treated promptly. The label specifically notes that this requires careful monitoring and replacement of fluids and electrolytes, as well as treatment with appropriate antidiarrheal medication under medical supervision.

Q: Are there specific vision changes associated with Иринотекан?

A: Official drug information indicates that the medicine may affect vision. Some patients may experience blurred vision, particularly within the first 24 hours after receiving the infusion.

Q: Does this medicine affect a person's ability to drive or operate machinery?

A: Regulatory summaries state that because the medicine may cause temporary effects such as dizziness or blurred vision, activities requiring full alertness, such as driving a car or operating heavy machinery, are generally avoided until the patient's individual response to the medication is clear.

How to Store and Dispose of Иринотекан?

The storage and disposal of Irinotecan concentrate are strictly governed by regulatory requirements due to its classification as a cytotoxic antineoplastic agent.

---

Official Storage Requirements

Condition Type	Requirement
Temperature (Unopened Vial)	Store at controlled room temperature (15 C to 30 C).
Light Protection	Store in the original carton to protect from light.
Prohibited Environment	The product must not be frozen (concentrate or diluted solution).

The drug's stability is concentration-dependent. The diluted infusion solution is stable for 24 hours when refrigerated (2 C to 8 C) or only 4 hours at room temperature.

Handling and Disposal

Irinotecan must be kept out of the sight and reach of children.

Because it is a cytotoxic drug, all unused medicine, associated waste, and containers must be disposed of as hazardous waste following specific local and national regulations. The unused portion of the diluted solution must be discarded.